Compare ON Holding AG (ONON) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ON Holding AG vs Sana Biotechnology Inc — how do they compare? ON Holding AG trades at $35.09 (market cap $11.38B), while Sana Biotechnology Inc trades at $2.79 (market cap $836.71M). The key difference: ON Holding AG is far larger — about 13.6× Sana Biotechnology Inc's market cap, and ON Holding AG is trading nearer its 52-week high, Sana Biotechnology Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold ON Holding AG for 22 Days and Sana Biotechnology Inc for 23 Days on average.
| ONON | SANA | |
|---|---|---|
Market Cap | $11.38B | $836.71M |
Volume | 13,732,872 | 4,507,444 |
Sector | Consumer Cyclical | Health |
52-Week High | $50.63 | $5.92 |
52-Week Low | $26.76 | $2.68 |
Typical Hold Time | 22 Days | 23 Days |
Enterprise Value | $10.54B | $749.96M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ONON trades at $34.04, up 2.47% today, with a bullish technical signal from moving averages but overbought oscillators. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $0.44 exceeding the $0.4203 estimate. Revenue reached $3.01B in 2025, with net income of $203.70M, and profitability metrics like a 64.82% gross margin and 23.95% ROE indicate operational strength. Recent news highlights a $1 billion share buyback plan and ambitious 2029 targets.
The outlook is positive, supported by analyst consensus with a $42.26 price target and 74% buy ratings. Key opportunities include direct-to-consumer growth and expansion into new sports categories, while risks involve competitive pressures and execution of long-term goals amid market volatility.
SANA Biotechnology trades at $2.79, up 2.57% today, but faces significant fundamental challenges with negative revenue, substantial losses, and bearish technical indicators. The company reported a net loss of $244.17 million in 2025 with no revenue, while technical analysis shows a bearish trend with moving averages and ADX indicators signaling selling pressure. Recent news highlights multiple investor conference presentations and ongoing legal scrutiny regarding fiduciary duties.
Despite strong analyst support (82% buy ratings), SANA's lack of revenue generation and negative profitability metrics present substantial investment risk. The company's cash flow remains negative, requiring continued financing. Near-term catalysts include upcoming Q3 earnings and clinical developments, but investors should weigh the high-risk profile against potential long-term biotechnology breakthroughs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About ON Holding AG
ON Holding AG is a Swiss sports company primarily known for its high-performance running shoes, apparel, and accessories under the 'On' brand. The company emphasizes a blend of high-end design, proprietary cloud technology (like CloudTec cushioning), and sustainability in its products. On has rapidly gained market share globally, appealing to both competitive athletes and general consumers in the performance and lifestyle footwear segments.
Read more on ONON →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
